Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Christine Rains
Period: Reporting periods mapped to calendar 2025 Q2 – 2025 Q4 (3 quarters; questions recorded in 2).
- Questions
- 2on tracked calls
- Challenge rate
- 0%none of 2 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 2with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 2 of 2 questions from 2 companies
CRLCharles River Laboratories1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q4
just hoping you can give some context on DSA cancellations in the quarter. I think you said they were consistent with last quarter levels
Show response
Jim confirmed cancellations have returned to normal historical levels after being elevated two years ago. Declined to share specific percentages or dollar amounts. Nine-month backlog allows effective slot replacement.
IQVIQVIA1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q2
hoping you can give some quantification about the delays you are seeing on new clinical projects
Show response
Bousbib said decision timelines remain elongated though some delayed programs are launching because clients can't wait. EBP funding relatively tame since beginning of year. Better bookings driven by proactive go-to-market and higher win rates, not market normalization.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| CRL Charles River Laboratories | 1 | —Rate withheld: fewer than 3 questions |
| IQV IQVIA | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | No questions recorded | — | — |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q3No questions recorded
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Demand2
- Regulation Policy1